Dapoflit GM 2 Tablet is an advanced triple-drug oral formulation combining Dapagliflozin 10mg, Glimepiride 2mg, and Metformin 1000mg, designed for effective and sustained management of type-2 diabetes mellitus in patients requiring intensified therapy.
Dapagliflozin promotes glucose excretion via the kidneys, Glimepiride stimulates insulin secretion from pancreatic beta cells, and Metformin reduces hepatic glucose production while improving insulin sensitivity. This multi-mechanism approach ensures optimal control of both fasting and post-meal blood glucose levels.
This combination is commonly prescribed by diabetologists and physicians for patients not adequately controlled on dual therapy. The higher Glimepiride strength supports enhanced insulin release, making it suitable for patients with progressive insulin deficiency.
Adding Dapoflit GM 2 Tablet strengthens your diabetes and metabolic-care segment, offering strong opportunities in chronic therapy supply, hospital distribution, pharmacy channels, institutional procurement, export markets, and third-party manufacturing. Its clinical relevance and high prescription frequency make it a commercially reliable product.